Head-To-Head Contrast: Abcam (ABCZF) vs. Its Rivals

Abcam (OTCMKTS:ABCZF – Get Free Report) is one of 374 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Abcam to similar companies based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.

Earnings and Valuation

This table compares Abcam and its competitors revenue, earnings per share and valuation.

Get Abcam alerts:

Abcam’s competitors have higher revenue, but lower earnings than Abcam. Abcam is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

43.6% of Abcam shares are owned by institutional investors. Comparatively, 24.5% of shares of all “Biotechnology” companies are owned by institutional investors. 25.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dividends

Abcam pays an annual dividend of C$0.07 per share and has a dividend yield of 0.3%. Abcam pays out 42.5% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 2.7% and pay out 11,176.7% of their earnings in the form of a dividend.

Analyst Ratings

This is a summary of current ratings for Abcam and its competitors, as provided by MarketBeat.

As a group, “Biotechnology” companies have a potential upside of 98.20%. Given Abcam’s competitors higher possible upside, analysts plainly believe Abcam has less favorable growth aspects than its competitors.

Profitability

This table compares Abcam and its competitors’ net margins, return on equity and return on assets.

Summary

Abcam beats its competitors on 6 of the 10 factors compared.

About Abcam

(Get Free Report)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.